Comparative Effectiveness of First-Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set.
Sabina CicirielloGeoffrey Owen LittlejohnTamas TreuerKathryn A GibsonEwa HaladyjPeter YoussefPaul BirdCatherine O'SullivanTegan SmithClaire T Deakinnull nullPublished in: ACR open rheumatology (2023)
In this comparative analysis, treatment persistence up to 24 months was significantly longer for first-line BARI compared with TNFi, but the effect size of 1.00 month is not clinically meaningful. There was no difference in persistence for BARI monotherapy versus combination therapy.